Under the hypothesis that Flt3L potentiates DC-mediated antigen presentation, pre-treatments with recombinant human Flt3L (CDX-301) before vaccination with CDX-1401, a DC-based vaccine targeting the tumor antigen NY-ESO-1, was tested in melanoma patients in a phase II clinical trial [74]. This evidence concerns the gene FLT3LG and melanoma.